Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Opposes 10-Nation WTO Proposal To Curb Drug Counterfeits

This article was originally published in PharmAsia News

Executive Summary

India had adopted a position opposing a proposal by 10 World Trade Organization members, most of them major entities, to block the counterfeiting of patented innovative drugs.

India had adopted a position opposing a proposal by 10 World Trade Organization members, most of them major entities, to block the counterfeiting of patented innovative drugs. India’s government contends the agreement was adopted at the urging of multinational drug makers that fear generic competition, primarily from India. At issue is the Anti-Counterfeiting Trade Agreement signed by Australia, Canada, Japan, Mexico, Morocco, New Zealand, Singapore, South Korea, Switzerland and the U.S. India said the proposal was an attack on generics produced not only by it, but by makers in Bangladesh, Brazil, China and Thailand. (Click here for more)

“India Opposes Pharma Piracy Pact By 10 Nations” Economic Times (India) (3/3/12)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC080709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel